Piper Jaffray is out with its report today on Orthofix OFIX, raising its PT from $35 to $37.
In a note to clients, Piper Jaffray writes, "We rate OFIX Neutral and are raising our PT to $37, from $35, based on 2012E EBITDA of $121 mil (prev. $116 mil) and a multiple of 6.5x (unchanged). Our 6.5x multiple is based on OFIX's current multiple on 2011E EBITDA. We assume year end 2011 net debt of $128 mil, and s/o of 17.9 mil."
At the time of posting, shares of OFIX were trading at $30.00, up 2.63% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentOrthofixPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in